SEARCH

SEARCH BY CITATION

Summary

  1. Top of page
  2. Summary
  3. Introduction
  4. Conclusion
  5. Acknowledgements
  6. References

Polycystic ovary syndrome (PCOS) is a common disorder but has considerable phenotypic variability and this has led to controversy over its exact definition and diagnosis. The objective of this study was to review the recently proposed diagnostic criteria to determine whether they were sufficiently robust for clinical and research practise. We have reviewed the literature pertaining to clinical measurement and quality of laboratory analysis in relation to clinical and biochemical hyperandrogenism. The recently published statements regarding the diagnosis of PCOS assume that the clinical, laboratory and imaging studies are dichotomous variables, without considering the effect of observer subjectivity or measurement variability on the outcome. The data suggest that there is considerable uncertainty of all measurements and lack of clarity of the definition of the term ‘hyperandrogenaemia’ which can lead to misdiagnosis. The current diagnostic strategies for PCOS are defined too vaguely to ascertain that individuals fit the definition of the syndrome. A pragmatic approach may be taken in the management of an individual depending upon her particular symptoms and needs. However, research into the epidemiology, pathophysiology and treatment of PCOS will require the production of robust definitions of the diagnostic criteria. We propose specific criteria that would answer the criticisms that we have raised.


Introduction

  1. Top of page
  2. Summary
  3. Introduction
  4. Conclusion
  5. Acknowledgements
  6. References

The evolution of the polycystic ovary syndrome (PCOS) has followed a typical career in medical folklore. Initially there were the case reports, then a brief case series and after an appropriate gestation came the recommendations, guidelines and consensus statements. However, as the spectrum and the implications of the syndrome have become better understood, so the poorly defined margins of the syndrome have led to a degree of unravelling of the consensus, not to mention confusion amongst gynaecologists and endocrinologists.1

The original case series of Stein and Leventhal described seven women with two apparent phenotypes, all of whom had enlarged polycystic ovaries and amenorrhoea.2 Over the years, this has been distilled down to a definition that encompasses chronic anovulation and hyperandrogenism after all other causes of irregular menses had been excluded. This definition reached a consensus supported by the National Institutes of Health (NIH) in 1990 even though in Europe and Australasia ovarian imaging had become an important component in the diagnosis, largely because ovarian morphology was part of the original disease description. Despite a high degree of concordance between the NIH consensus and the European addition of ovarian imaging, it became necessary to try to gain transatlantic harmony with a new consensus held under the auspices of the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM) which resulted in what are known as the Rotterdam criteria.3

The proposal agreed in Rotterdam was that PCOS should be diagnosed on the basis of the presence of two out of the following three features: oligo- or anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries. This has therefore created the possibility of several phenotypes and the recognition that PCOS is a syndrome with heterogeneity in its constellation of features. This has led to some disagreement4,5 and a series of studies considering the phenotypes of PCOS that have been added to the syndrome which have had the effect of increasing the patient base by a factor of approximately 20%6 compared with the NIH consensus and is more in line with European prevalence data.7 Indeed, there has been a subsequent position statement from the Androgen Excess Society trying to bond the NIH and Rotterdam positions.8 It is generally recognized that the Rotterdam consensus criteria now include women with PCOS who have a milder disease and are also less likely to be overweight6 (see Table 1).

Table 1.  Criteria for the diagnosis of polycystic ovary syndrome (PCOS)
  • NIH, National Institutes of Health;

    ESHRE/ARMS, European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine.

NIH (1990)To include all of the following:
1: Hyperandrogenism and/or hyperandrogenaemia
2: Oligo-ovulation
3: Exclusion of related disorders
ESHRE/ARMS (Rotterdam 2003)To include two of the following, including the exclusion of related disorders:
1: Oligo- or anovulation
2: Clinical and/or biochemical signs of hyperandrogenism
3: Polycystic ovaries
Androgen Excess Society (2006)To include all of the following:
1: Hirsutism and/or hyperandrogenaemia
2: Oligo-anovulation and/or polycystic ovaries
3: Exclusion of androgen excess or related disorders

We feel that a major aspect of PCOS that has not been given adequate emphasis is in the metrics of the diagnostic characteristics. Although these are well known, are they sufficiently defined so as to be the anchors for diagnosis? Are they repeatable, robust and sufficiently reliable to allow data from one study to be compared with another? We believe they are not.

Clinical hyperandrogenism

Acne, hirsutism and androgenic alopecia are due to androgenic stimulation of the pilosebaceous unit and all occur in women with PCOS. The exact prevalence of these conditions in the wider population is not precisely known. Acne occurs in almost all teenagers and a degree of physiological acne occurs in 54% of women over 25 years of age with 3% showing clinical acne.9 A study of pregnant women reported that 26% complained of acne prior to pregnancy10 and a study of PCOS reported that 58% of their control women had acne.11 These proportions of unselected populations with acne make the link with PCOS unconvincing until sufficiently powered studies or studies including appropriate acne grading are performed.

The position for hirsutism is complicated by the fact that the standard scoring system designed by Ferriman and Gallwey in London defined abnormal hair growth in mathematical terms, that is, more that two standard deviations above the mean or approximately 1·2% of the population.12 DeUgarte et al. confirmed this finding but clarified that many women with lesser hair scores were using hair removal therapies indicating a mismatch between patient and physician scores.13 The UK Institute of Electrology report that 80% of women have some sort of unwanted hair.14

The diagnosis of hirsutism can be very subjective and should it be defined by the patient or her physician?15 Is a woman with facial hair but no body and limb hair more or less hirsute than a woman with a hairless face but hairy trunk and limbs? A systematic study of hair growth in Scandinavian women showed that there was an 18% overlap in hair growth scores between women complaining of hirsutism and a similar sized control group.16 And of course the same situation occurs with acne and women who are obese are more likely to find their hair and acne more troublesome.13,17

There are several scoring systems for hirsutism but the vast majority of investigators now use the system devised by Ferriman and Gallwey in which the body is divided into 11 zones, each of which is scored 0–4 on a subjective basis. Nine of the zones are used to compute a hirsutism score. There is no flexibility within this system to allow for nonstandard patterns of hair growth. This is a serious deficiency as women exhibit several different patterns of facial and body hair growth and are more likely to present with hirsutism if they have hair growth on the face, chest and upper back than on other sites.18 The score is likely to be inflated by hairy thighs which occur in 45% of premenopausal Scandinavian women16 and hair on this site does not appear to respond to antiandrogen therapy.19

A greater problem lies in the standardization of hair growth scores. We have previously described the difference in mean (and variance) of hair growth scores between studies.20 The severity of hirsutism should be fairly similar between studies as subjects recruited need to be sufficiently hirsute for adequate hair scores to be made before and after treatment. Yet the difference is great, and our reason for this prejudice is that this is largely due to variation in observer scores; this has been confirmed by Wild et al. who reported a within patient difference in Ferriman and Gallwey hair scores of 12 points between different members of his own research group, and for which the maximum score is only 36.21 Furthermore, only a tiny minority of studies report the investigator variability in this key clinical measurement in comparison with the extensive quality data for laboratory measurements.

As acne occurs in a significant number of women after the age of 25 years, how can it be considered a feature of PCOS unless it is defined as abnormal? Although the dermatological literature is replete with scoring systems which have been shown to be reproducible from photographic images,22 the PCOS literature merely indicates the presence or absence of acne.

The position for androgenetic alopaecia is less clear. Whilst it is undoubtedly an androgen-mediated process, there has been difficulty relating this type of hair loss to increased circulating androgens23,24 and a link to polycystic ovaries has been proposed.25 Indeed, it may be related more closely to iron deficiency than androgens.24 Despite this there are two well-recognized patterns of androgen-mediated hair loss26,27 and the incidence of balding in premenopausal women in the UK is 13%.28

Biochemical hyperandrogenism

None of the myriad of PCOS guidelines give any real indication of the definition of the term biochemical hyperandrogenaemia, although some of the issues were raised in the Rotterdam consensus paper.3 There is a lack of clarity on which androgen should be measured, how often should it/they be measured to exclude normal values, what is a normal androgen and which analytical technique should be employed. The latter aspect has been addressed by the Endocrine Society in a recent position paper but its strength is in highlighting the problems rather than solutions.29 However, even this paper fails to mention that one of the better performing direct testosterone assays is beset by a significant cross reactivity with dehydroepiandrosterone sulphate (DHEAS).30

First, which androgen should be measured? There is an implication that testosterone, both total and free, DHEAS and possibly androstenedione should be measured. There are significant issues raised over the analytical performance of free testosterone assays and therefore an alternative is the free androgen index [(total testosterone / sex hormone binding globulin (SHBG)) × 100] but this will be dependent on another measurement – SHBG, itself influenced by the degree of hyperinsulinaemia. There appears to be an underlying philosophy in the guidelines that the aim should be to identify a state of biochemical hyperandrogenism and this is the reason for including free testosterone because it is more frequently elevated. However, this is a circular argument as an elevated androgen is a diagnostic criterion. Nevertheless, it should be noted that most laboratories define their reference limits as 95% confidence intervals and therefore 2·5% of the normal population will be above these limits. If the four androgens mentioned above are measured there will be a 10% chance that one will be abnormal and this will be increased if calculated variables are included. It should be obvious that if subjects are investigated on multiple occasions, then the chance of an abnormal result will increase by multiples on each occasion.

Second, what is a normal value? The Endocrine Society position statement suggests that each laboratory should collaborate with its endocrinologists to determine its own reference limits for testosterone. This is good practice but reference limits require a population of 120 subjects and when one considers the range of preanalytical factors that influence serum testosterone (see Table 2), it is clear that this is not practicable for any other than a research unit. The sum of the factors relating to day-to-day variation of total testosterone measurement have been considered by the assessment of its biological variation in both women with and without PCOS. Samples taken in the morning throughout the cycle showed an individual index of variation of 0·43% and 0·69%, respectively.31

Table 2.  Factors that are known to alter serum testosterone concentrations
Physiological factors
Pulsatile release during the day44
Diurnal rhythm: am > pm42,45,46
Menstrual cycle: luteal > follicular31,47
Season (no variation in total testosterone free testosterone shows 30% difference): summer > winter43,48
Age (years) in women with and without polycystic ovary syndrome (PCOS): 20s > 40s49,50
Analytical factors
Cross reactivity with other endogenous steroids30
Interference by endogenous antibodies51
Poor performance in the female range: < 8 nmol/l1,29

Moreover, the data in the table has been based on immunoassays, some of which will have been direct, and will potentially need to be repeated with mass spectrometry techniques as these become routinely available.32 Finally, it has been proposed that even subjects with normal circulating androgens on repeated testing can exhibit an occult form of hyperandrogenaemia which is uncovered by hCG stimulation testing.33

The Rotterdam consensus has discarded the use of LH and FSH ratios as diagnostic criteria which is a good decision. Fauser et al.34 showed that only 50% of patients with polycystic ovaries (PCO) had an elevated LH and 43% of patients with high LH had PCO. Given the population of 99 subjects of whom 35 had ultrasound proven PCO, a single LH measurement has a positive predictive power (PPV) of only 18%; if we reduce the prevalence to 7% as in the populations described by Escobar-Morreale et al.35 and Knockenhauer et al.,36 the PPV falls further to 3·6%.

There is an inherent problem in developing a robust definition of hyperandrogenaemia as it is one of the defining characteristics of PCO. It is therefore only possible to define the term in a negative way. Moreover, because the incidence of PCOS, as opposed to the presence of polycystic ovaries, has only recently been established (see above), the majority of previous studies of the diagnostic performance of circulating androgens are fatally flawed, as they did not include sufficient controls to balance the appropriate incidence of PCOS.

Assessment of anovulation

Anovulation is assessed by measuring the serum progesterone during the mid-luteal phase. The peak value for progesterone only remains for a short time. Indeed, the commonest reason for a low value is that the sample was not taken at the appropriate time. The most widely used value in the UK to indicate ovulation is 30 nmol/l on Day 21. It is of note that there is significant bias between methods currently available and this is not reflected by the interpretation given on laboratory report forms.37 This bias currently ranges +12% to –14% between the lowest and the highest different method means and this clearly introduces further diagnostic confusion regarding the ovulatory status of an individual.

Ovarian imaging

The definition of polycystic ovaries in the Rotterdam consensus was based on an assessment of the published data correlating the ‘best fit’ for ultrasound morphology with endocrine and clinical features of the syndrome.38 Since the publication, there have been papers questioning the defining characteristics. Should the stroma be included?6 Is the ovarian volume correct?39 Is it sufficient to include only 12 follicles?40 However, the most important recent finding which agrees with the argument above for clinical examination and biochemical measurements is that ultrasound imaging are markedly dependent on the operator. Amer and colleagues41 recorded 27 scans and showed them randomly in duplicate to four experienced imagers. The four imagers agreed with themselves in 63–74% of the cases whereas the observers agreed with each other in only 51% of the cases, which showed a high probability of inconsistency between operators.

Proposal for new criteria

We suggest that formal definitions be developed and propose the following criteria:

Clinical hyperandrogenism.  All studies use and cite well-validated scoring systems for acne, balding and hirsutism and include the within and between investigator variability.

Laboratory hyperandrogenism.  In order to reduce variability, we would suggest that a single blood sample for testosterone is taken in the morning on Days 1–5 of a menstrual cycle. Specific criteria will need to be addressed for women with amenorrhoea. Measurement of multiple analytes will serve only to add variation and should not be used in the definition. The testosterone method and precision should be cited; and age-related reference ranges for that method should be developed from a cohort of at least 120 subjects who are defined as not having PCOS using clinical and imaging technique alone so that the diagnosis is not affected by testosterone method bias.

Diagnosis of anovulation.  The progesterone method and precision used to confirm anovulation should be cited and the analytical bias relative to an international reference preparation should be stated, for example, Institute for Reference Materials and Methods (http://www.irmm.jrc.be).

Ultrasound.  Specific criteria for ultrasound imaging have already been addressed.38

Insulin sensitivity.  There is considerable interest in insulin sensitivity in PCOS and consideration should be given to including this variable in the diagnostic strategy. However, at present there may be too many preanalytical42 and analytical issues43 to allow this diagnostic test to be included.

Conclusion

  1. Top of page
  2. Summary
  3. Introduction
  4. Conclusion
  5. Acknowledgements
  6. References

The PCOS is a well-recognized condition that causes considerable morbidity. However, the current diagnostic strategies for PCOS are defined too vaguely to ascertain that individuals fit the definition of the syndrome. Clinical examination is hindered by imprecise scoring systems; the laboratory analytical techniques and reference ranges are inadequate. Finally the lynchpin of diagnosis – imaging – appears to be irreproducible. A pragmatic approach may have to be taken in the management of the individual depending upon her particular symptoms and needs. Nevertheless, research into the epidemiology, pathophysiology and treatment of PCOS will require the production of robust definitions of the diagnostic criteria.

Acknowledgements

  1. Top of page
  2. Summary
  3. Introduction
  4. Conclusion
  5. Acknowledgements
  6. References

We are grateful to Prof. Ricardo Azziz for useful advice and the Clinical Science Reviews Committee of the Association for Clinical Biochemistry for their encouragement.

References

  1. Top of page
  2. Summary
  3. Introduction
  4. Conclusion
  5. Acknowledgements
  6. References
  • 1
    Cussons, A.J., Stuckey, B.G.A., Walsh, J.P., Burke, V. & Norman, R.J. (2005) Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clinical Endocrinology, 62, 289295.
  • 2
    Stein, I.F. & Leventhal, M.L. (1935) Amenorrhoea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology, 29, 181191.
  • 3
    The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. (revised 2003) Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19, 4147.
  • 4
    Azziz, R. (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. Journal of Clinical Endocrinology and Metabolism, 91, 781785.
  • 5
    Franks, S. (2006) Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. Journal of Clinical Endocrinology and Metabolism, 91, 786789.
  • 6
    Belosi, C., Selvaggi, L., Apa, R., Guido, M., Romualdi, D., Fulghesu, A.M. & Lanzone, A. (2006) Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma. Human Reproduction, 21, 31083115.
  • 7
    Balen, A.H. & Michelmore, K. (2002) What is polycystic ovary syndrome? Are national views important? Human Reproduction, 17, 22192227.
  • 8
    Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Futterweit, W., Janssen, O.E., Legro, R.S., Norman, R.J., Taylor, A.E. & Witchel, S.F. (2006) Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Journal of Clinical Endocrinology and Metabolism, 91, 42374245.
  • 9
    Goulden, V., Stables, G.I. & Cunliffe, W.J. (1999) Prevalence of facial acne in adults. Journal of the American Academy of Dermatology, 41, 577580.
  • 10
    Rushton, H., Lyons, G.M., Firth, P.S., Abrahams, R. & James, K.C. (1986) Scalp hair, facial skin and pregnancy. Journal of Obstetrics and Gynaecology, 7, 5152.
  • 11
    Welt, C.K., Gudmundsson, J.A., Arason, G., Adams, J., Palsdottir, H., Gudlaugsdottir, G. & Ingadottir, Crowley, W.F. (2006) Characterising discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. Journal of Clinical Endocrinology and Metabolism, 91, 48424848.
  • 12
    Ferriman, D. & Gallwey, J.D. (1961) Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology, 21, 14401447.
  • 13
    DeUgarte, C.M., Woods, K.S., Bartolucci, A.A. & Azziz, R. (2006) Degree of facial and body terminal hair growth in unselected black and white women: toward a population definition of hirsutism. Journal of Clinical Endocrinology and Metabolism, 91, 13451350.
  • 14
    British Institute and Association of Electrolysis. http://www.electrolysis.co.uk/index.html (accessed 26 February 2007).
  • 15
    Barth, J.H. (1997) How hairy are hirsute women? Clinical Endocrinology, 47, 255260.
  • 16
    Lunde, O. & Grottum, P. (1984) Body hair growth in women: normal or hirsute. American Journal of Physical Anthropology, 64, 307313.
  • 17
    Barth, J.H., Catalan, J., Cherry, C.A. & Day, A.E. (1993) Psychological morbidity in women referred for treatment of hirsutism. Journal of Psychosomatic Research, 37, 615619.
  • 18
    Shah, P.N. (1957) Human body hair – a quantitative study. American Journal of Obstetrics and Gynecology, 73, 12551265.
  • 19
    Barth, J.H., Cherry, C.A., Wojnarowska, F. & Dawber, R.P.R. (1991) Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clinical Endocrinology, 35, 510.
  • 20
    Barth, J.H. (1996) How robust is the methodology for trials of therapy in hirsute women? Clinical Endocrinology, 45, 379380.
  • 21
    Wild, R.A., Vesely, S., Beebe, L., Whitsett, T. & Owen, W. (2005) Ferriman Gallwey self-scoring 1: performance assessment in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 41124114.
  • 22
    Gibson, J.R., Harvey, S.G., Barth, J.H., Darley, C.R., Reshad, H.R. & Burke, C.A. (1984) Assessing inflammatory acne vulgaris: correlation between clinical and photographic methods. British Journal of Dermatology, 111 (Suppl. 27), 168170.
  • 23
    De Villez, R.L. & Dunn, J. (1986) Female androgenic alopecia: the 3 alpha,17 beta-androstanediol glucuronide/sex hormone binding globulin ratio as a possible marker for female pattern baldness. Archives of Dermatology, 122, 10111015.
  • 24
    Rushton, D.H., Ramsay, I.D., James, K.C., Norris, M.J. & Gilkes, J.J. (1990) Biochemical and trichological characterization of diffuse alopecia in women. British Journal of Dermatology, 123, 187197.
  • 25
    Cela, E., Robertson, C., Rush, K., Kousta, E., White, D.M., Wilson, H., Lyons, G., Kingsley, P., McCarthy, M.I. & Franks, S. (2003) Prevalence of polycystic ovaries in women with androgenic alopecia. European Journal of Endocrinology, 149, 439442.
  • 26
    Ludwig, E. (1977) Classification of the types of androgenic alopecia (common baldness) arising in the female sex. British Journal of Dermatology, 97, 247254.
  • 27
    Norwood, O.T.T. (1975) Male pattern baldness: classification and incidence. Southern Medical Journal, 68, 13591365.
  • 28
    Venning, V.A. & Dawber, R.P.R. (1988) Patterned androgenic alopecia. Journal of the American Academy of Dermatology, 18, 10731078.
  • 29
    Rosner, W., Auchus, R.J., Azziz, R., Sluss, P.M. & Raff, H. (2007) Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism, 92, 405413.
  • 30
    Warner, M.H., Kane, J.W., Atkin, S.L. & Kilpatrick, E.S. (2006) Dehydroepiandrosterone sulphate interferes with the Abbott Architect direct immunoassay for testosterone. Annals of Clinical Biochemistry, 43, 196199.
  • 31
    Jayagopal, V., Kilpatrick, E.S., Jennings, P.E., Hepburn, D.A. & Atkin, S.L. (2003) The biological variation of testosterone and sex hormone binding globulin (SHBG) in polycystic vary syndrome: implications for SHBG as a surrogate marker of insulin resistance. Journal of Clinical Endocrinology and Metabolism, 88, 15281533.
  • 32
    Cawood, M.L., Field, H.P., Ford, C.G., Gillingwater, S., Kicman, A., Cowan, D. & Barth, J.H. (2005) Testosterone measurement by isotope-dilution liquid chromatography-tandem mass spectrometry: validation of a method for routine clinical practise. Clinical Chemistry, 51, 14721479.
  • 33
    Gilling-Smith, C., Story, H., Rogers, V. & Franks, S. (1997) Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clinical Endocrinology, 47, 9399.
  • 34
    Fauser, B.C.J.M., Pache, T.D., Hop, W.C.J., De Jong, F.H. & Dahl, K.D. (1992) The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates. Clinical Endocrinology, 37, 445452.
  • 35
    Escobar-Morreale, H.F., Asuncion, M., Calvo, R.M., Sancho, J. & San Millan, J.L. (2001) Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies. European Journal of Endocrinology, 145, 619624.
  • 36
    Knochenhauer, E.S., Key, T.J., Kahsar-Miller, M., Waggoner, W., Boots, L.R. & Azziz, R. (1988) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism, 83, 30783082.
  • 37
    Middle, J.G. & UK NEQAS. (2006) Steroid Hormones Annual Review for Progesterone. (Available from the author at UK NEQAS, PO Box 3909, Birmingham B15 2UE, UK).
  • 38
    Balen, A.H., Laven, J.S.E., Tan, S.L. & Dewailly, D. (2003) Ultrasound assessment of the polycystic ovary: international consensus definitions. Human Reproduction Update, 9, 505514.
  • 39
    Jonard, S., Robert, Y. & Dewailly, D. (2005) Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries? Human Reproduction, 20, 28932898.
  • 40
    Allemand, M., Tummon, I.S., Phy, J.L., Foong, S.C., Dumesic, D.A. & Session, D.R. (2006) Diagnosis of polycystic ovaries by three dimensional transvaginal ultrasound. Fertility and Sterility, 85, 214219.
  • 41
    Amer, S.A.K.S., Li, T.C., Bygrave, C., Sprigg, A., Sravelos, H. & Cooke, I.D. (2002) An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries. Human Reproduction, 17, 16161622.
  • 42
    Jayagopal, V., Kilpatrick, E.S., Holding, S., Jennings, P.E. & Atkin, S.L. (2002) The biological variation of insulin resistance in polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 87, 15601562.
  • 43
    Marcovina, S., Bowsher, R.R., Miller, W.G., Staten, M., Myers, G., Caudill, S.P., Campbell, S.E. & Steffes, M.W. for the Insulin Standardization Workgroup (2007) Standardization of insulin immunoassays: report of the American Diabetes Association workgroup. Clinical Chemistry, 53, 711716.
  • 44
    Rickenlund, A., Thoren, M., Carlstrom, K., Von Schoultz, B. & Hirschberg, A.L. (2004) Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes. Journal of Clinical Endocrinology and Metabolism, 89, 702707.
  • 45
    Garde, A.H., Hansen, A.M., Skovgaard, L.T. & Christensen, J.M. (2000) Seasonal and biological variation of blood concentrations of total cholesterol, dehydroepiandrosterone sulfate, hemoglobin A (1c), IgA, prolactin, and free testosterone in healthy women. Clinical Chemistry, 46, 551559.
  • 46
    Azziz, R., Bradley, E. Jr, Huth, J., Boots, L.R., Parker, C.R. Jr & Zacur, H.A. (1990) Acute adrenocorticotropin-(1–24) (ACTH) adrenal stimulation in eumenorrheic women: reproducibility and effect of ACTH dose, subject weight, and sampling time. Journal of Clinical Endocrinology and Metabolism, 70, 12731279.
  • 47
    Massafra, C., De Felice, C., Agnusdei, D.P., Gioia, D. & Bagnoli, F. (1999) Androgens and osteocalcin during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism, 84, 971974.
  • 48
    Maes, M., Mommen, K., Hendrickx, D., Peeters, D., D’Hondt, P., Ranjan, R., De Meyer, F. & Scharpe, S. (1997) Components of biological variation, including seasonality, in blood concentrations of TSH, TT3, FT4, PRL, cortisol and testosterone in healthy volunteers. Clinical Endocrinology, 46, 587598.
  • 49
    Winters, S.J., Talbott, E., Guzick, D.S., Zborowski, J. & McHugh, K.P. (2000) Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertility and Sterility, 73, 724729.
  • 50
    Zumoff, B., Strain, G.W., Miller, L.K. & Rosner, W. (1995) Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. Journal of Clinical Endocrinology and Metabolism, 80, 14291430.
  • 51
    Torjesen, P.A. & Bjoro, T. (1996) Antibodies against [125I] testosterone in patient's serum: a problem for the laboratory and the patient. Clinical Chemistry, 42, 20472048.